SEBIA
Acquired by
CVC
SEBIA acquired by CVC
Target
SEBIA
Acquirer
CVC
Context
CVC and the Canadian company CDPQ are acquiring control of the medical diagnostics specialist Sebia. The company is valued at nearly EUR2 billion, according to multiple sources.
This transaction is part of the Healthcare & Pharma industry, which currently tracks an average EBITDA multiple of 12.8x since the beginning of 2026, 1.8% increase compared to 2025. This data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.
-> Deep-dive in Healthcare & Pharma market trends
Target
A global leader in in-vitro diagnostics (IVD), specializing in clinical electrophoresis technology. Founded in 1967, Sebia provides automated equipment and reagents used by medical laboratories worldwide to screen and monitor diseases such as multiple myeloma, metabolic disorders (diabetes), and hemoglobinopathies. The company generates over 90% of its sales internationally and has a direct presence in 15 countries.
Ent. Value
LOGIN
Equity Value
LOGIN
Multiples Analysis
EV / Revenue
LOGIN
EV / EBITDA
LOGIN
EV / EBIT
LOGIN
Historical Financials (EUR)
Other operations with SEBIA
| Date | Acquirer | Target | Country | Sector | Deal Context |
|---|---|---|---|---|---|
| 08/2025 | WARBURG PINCUS | SEBIA | FRANCE | Diagnostic Equipment | The French medical diagnostics giant Sebia welcomes a new heavyweight investor, Warburg Pincus, into its capital. This transaction, valuing the company at over EUR5 billion, sees the partial exit of minority shareholders CDPQ and ICG. The current majority owners, CVC Capital Partners and Tethys Invest (the Bettencourt-Meyers family office), retain a significant stake and will continue to back the company alongside Warburg Pincus. This new consortium aims to support Sebia's expansion in the US and Asian markets and fund potential acquisitions in the IVD space. |
mynth data is contributed by M&A / PE professionals and systematically cross-verified against private deal documents and official releases. All source materials are destroyed post-validation to guarantee data anonymity and compliance.